The United Kingdom’s ambitious plans to foster growth within its vital life sciences sector are facing significant headwinds, with industry…
Read More
AbbVie Secures FDA Approval for Ultra-Rare Blood Cancer Therapy, While AstraZeneca Faces Delay for Breast Cancer Drug
The U.S. Food and Drug Administration (FDA) has recently issued a significant approval for AbbVie’s antibody-drug conjugate (ADC) targeting blastic…
Read More
Europe Faces a Decade-High Surge in Sexually Transmitted Infections, Highlighting Urgent Need for Enhanced Prevention and Treatment Strategies
New data released by Europe’s leading infectious disease agency reveals a concerning decade-high surge in bacterial sexually transmitted infections (STIs),…
Read More
Takeda Ordered to Pay $885 Million in Landmark "Pay-for-Delay" Drug Case, Faces Potential $2.5 Billion Liability
In a groundbreaking verdict that could reshape pharmaceutical antitrust litigation, a U.S. jury has found Japanese pharmaceutical giant Takeda liable…
Read More
Eli Lilly Faces Regulatory Scrutiny Over Foundayo’s Long-Term Safety Profile
Eli Lilly has swiftly responded to concerns raised by the US Food and Drug Administration (FDA) regarding the long-term safety…
Read More
MEDVi’s Meteoric AI-Fueled Ascent Faces Scrutiny Amidst FDA Warnings, Allegations of Deceptive Marketing, and Multiple Lawsuits
A telehealth startup, MEDVi, recently lauded by The New York Times as a prime example of an AI-driven billion-dollar enterprise,…
Read More
MEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric Growth
In an era increasingly shaped by the transformative power of artificial intelligence, a Los Angeles-based telehealth startup, MEDVi, has captured…
Read More
TrumpRx.gov: A Federal Portal Faces Scrutiny Amidst Concerns Over Direct-to-Consumer Drug Sales and Patient Safety.
As of early February, the federal portal TrumpRx.gov remains in a nascent state, displaying only a stylized Oval Office portrait…
Read More
